The article that appeared on page 185 in the February 1, 2014 issue included a footnote section which incorrectly stated the following:
The device(s)/drug(s) that is/are the subject of this manuscript is/are being evaluated as part of an ongoing FDA-approved investigational protocol (IDE) or corresponding national protocol.
However, the correct statement should be:
The device(s)/drug(s) that is/are the subject of this manuscript is/are not FDA-approved for this indication and is/are not commercially available in the United States. Actifuse was utilized in an on-label fashion whereas rhBMP-2 is considered “off-label” use in the setting of transforaminal lumbar interbody fusion. This was an independent study.
1. Nandyala SV, Marquez-Lara A, Fineberg SJ, Pelton M, Singh K. Prospective, randomized, controlled trial of silicate-substituted calcium phosphate versus
rhBMP-2 in a minimally invasive transforaminal lumbar interbody fusion. Spine 2014;39:185–191.